Practical guidance on intensification of insulin therapy with BIAsp 30: A consensus statement

International Journal of Clinical Practice

Volumn 63, Issue 11, 2009, Pages 1571-1577

  Unnikrishnan, A G ^a   Tibaldi, J ^b   Hadley Brown, M ^c   Krentz, A J ^d   Ligthelm, R ^e   Damci, T ^f   Gumprecht, J ^g   Ger, L ^h   Mu, Y ⁱ   Raz, I ^j  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Diabetes and Endocrinology   (United States)

^c Norfolk Primary Care Trust   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e EHM Clinic   (Netherlands)

^f ISTANBUL UNIVERSITY   (Turkey)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ CHINESE PLA GENERAL HOSPITAL   (China)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; ANTIDIABETIC AGENT; INSULIN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; ISOPHANE INSULIN;

ALGORITHM; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; GENERAL PRACTITIONER; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; TREATMENT FAILURE;

ALGORITHMS; BIPHASIC INSULINS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN, ISOPHANE; TREATMENT FAILURE;

EID: 70349939595     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02192.x     Document Type: Conference Paper

References (31)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 : 1047 1053.
2. Hjelm K, Mufunda E, Nambozi G, Kemp J. Preparing nurses to face the pandemic of diabetes mellitus: a literature review. J Adv Nurs 2003 41 : 424 434.
3. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995 44 : 1249 1258.
4. Mahler RJ, Adler ML. Clinical review 102: type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999 84 : 1165 1171.
5. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996 45 : 633 638.
6. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999 7 : 139 153.
7. Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. MedGenMed 2007 9 : 12.
8. Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther 2004 26 : 889 901.
9. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007 30 : 263 269.
10. Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study Int J Clin Pract 2008 62 : 1013 1018.
11. Bebakar WM, Chow CC, Kadir KA et al. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007 9 : 724 732.
12. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006 8 : 58 66.
13. Valensi P, Benroubi M, Borzi V et al. The IMPROVE study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008 62 : 1809 1819.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
15. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 412.
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. P10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
17. Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 13 (Suppl. 1 1 68.
18. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels : International Diabetes Federation, 2005. http://www.idf.org/webdata/ docs/IDF%20GGT2D.pdf (accessed June 2009).
19. Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N. Insulin for type 2 diabetes: choosing a second-line insulin regimen. Int J Clin Pract 2008 62 : 1647 1653.
20. Williams R. Breaking the barriers for improved glycaemic control: primary care and secondary care interface. Diabet Med 1998 15 (Suppl. 4 S37 40.
21. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 3086.
22. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006 28 : 1569 1581.
23. Liebl A, Prager R, Binz K et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009 11 : 45 52.
24. Gumprecht J, Benroubi M, Borzi V et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009 63 : 966 972.
25. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003 17 : 307 313.
26. Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract 2006 72 : 265 270.
27. Lund SS, Tarnow L, Nielsen BB, Parvin HH, Pedersen O, Vaag AA. Efficacy and safety of BIAsp 30 (Biphasic insulin aspart 30) TID in combination with oral hypoglycaemic agents in non-obese patients with type 2 diabetes. Diabetologia 2007 50 (Suppl. 1 S409.
28. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 265.
29. Ligthelm RJ. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Primary Care Diabetes 2009 3 : 97 102.
30. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008 10 : 247 256.
31. Kooy A, de Jager J, Lehert P et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009 169 : 616 625.